Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5137287 | 1.00 | C5AR1 (0.52) | C5AR1SMN1; SMN2TDP1LMNAL3MBTL1 | |
| SCHEMBL5135817 | 0.93 | C5AR1 (0.48) | C5AR1SMN1; SMN2TDP1LMNAL3MBTL1 | |
| SCHEMBL5135814 | 0.93 | C5AR1 (0.48) | C5AR1SMN1; SMN2TDP1LMNAL3MBTL1 | |
| SCHEMBL5136279 | 0.93 | C5AR1 (0.48) | C5AR1SMN1; SMN2TDP1LMNAL3MBTL1 | |
| SCHEMBL5136277 | 0.93 | C5AR1 (0.48) | C5AR1SMN1; SMN2TDP1LMNAL3MBTL1 | |
| SCHEMBL5134977 | 0.93 | C5AR1 (0.48) | C5AR1SMN1; SMN2TDP1LMNAL3MBTL1 | |
| SCHEMBL5134973 | 0.93 | C5AR1 (0.48) | C5AR1SMN1; SMN2TDP1LMNAL3MBTL1 | |
| SCHEMBL5135981 | 0.91 | C5AR1 (0.47) | C5AR1SMN1; SMN2TDP1LMNAL3MBTL1 | |
| SCHEMBL5135979 | 0.91 | C5AR1 (0.47) | C5AR1SMN1; SMN2TDP1LMNAL3MBTL1 | |
| SCHEMBL5134942 | 0.90 | C5AR1 (0.55) | C5AR1SMN1; SMN2TDP1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |